Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

SEHK:1258
SEHK:1258Metals and Mining

Why China Nonferrous Mining (SEHK:1258) Is Down 5.0% After Resuming Full Output And Issuing 2026 Guidance

China Nonferrous Mining Corporation Limited recently reported that rehabilitation of the main and auxiliary shafts at Chambishi Southeast Mine was completed in December 2025, allowing the operation to resume full production on 1 January 2026. Alongside this, the company issued 2026 production guidance outlining approximately 484,000 tonnes of overall copper output and diversified by-products, giving investors clearer visibility into future operating volumes and product mix. We will now...
NasdaqGS:SDGR
NasdaqGS:SDGRHealthcare Services

Is Manas AI’s Platform Deal Reshaping the Investment Case For Schrödinger’s (SDGR) Drug Discovery Model?

In January 2026, Manas AI announced a multi-year agreement granting it extensive access to Schrödinger’s physics-based computational drug discovery platform and expert support, aimed at integrating this technology with its AI “world model” for identifying diverse molecular binders. A key angle for investors is that Schrödinger’s tools will be tightly embedded into Manas AI’s large-scale discovery workflows, potentially reinforcing Schrödinger’s position in AI-enabled molecular design...
NYSE:FDP
NYSE:FDPFood

Fresh Del Monte (FDP) Valuation Check As Sales Stagnation And Forecast Revenue Decline Raise New Questions

Why Fresh Del Monte Produce Is Back in Focus Fresh Del Monte Produce (FDP) is back on investors’ radar after reports of several years of stagnant sales and a forecasted 2.9% revenue decline, raising fresh questions about demand and the company’s growth options. See our latest analysis for Fresh Del Monte Produce. Against concerns about softer demand, Fresh Del Monte Produce’s share price has moved to $38.12, with a 30 day share price return of 5.98% and a 90 day gain of 10.91%. Its 1 year...
NasdaqGS:IBRX
NasdaqGS:IBRXBiotechs

Why ImmunityBio (IBRX) Is Up 16.8% After New ANKTIVA Data, FDA Progress And Saudi Approvals

In recent weeks, ImmunityBio has reported updated Phase 2 data in recurrent glioblastoma, advanced FDA discussions on its ANKTIVA bladder cancer filings, and secured Saudi approvals for ANKTIVA in both non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. Together, these developments highlight ImmunityBio’s attempt to build a broad immunotherapy platform spanning checkpoint-experienced lung cancer, bladder cancer, and chemo-free cell therapy combinations in...
ENXTPA:SW
ENXTPA:SWHospitality

Assessing Sodexo (ENXTPA:SW) Valuation After A Year Of Share Price Weakness

How Sodexo’s recent share performance frames today’s opportunity Sodexo (ENXTPA:SW) has been under pressure, with the share price showing a 19% decline over the past 3 months and a 37% decline over the past year. This comes despite revenue of €24.1b and net income of €695m. See our latest analysis for Sodexo. The recent 1 day share price return of a 1.1% decline and 90 day share price return of an 18.8% decline, alongside a 1 year total shareholder return of a 36.5% decline, points to fading...
NasdaqGS:LOPE
NasdaqGS:LOPEConsumer Services

The Bull Case For Grand Canyon Education (LOPE) Could Change Following Conflicting Analyst And Investor Sentiment - Learn Why

In recent months, Barrington Research has repeatedly reaffirmed its “Outperform” rating on Grand Canyon Education, underscoring confidence in the company’s business performance amid sector headwinds and regulatory uncertainties. At the same time, Riverwater Partners highlighted Grand Canyon Education as a major short-term detractor while still describing it as a high-quality operator with resilient demand and strong returns on invested capital. Next, we’ll examine how this combination of...
NasdaqGM:ORKA
NasdaqGM:ORKABiotechs

How Early ORKA-002 Dosing Data At Oruka Therapeutics (ORKA) Has Changed Its Investment Story

Oruka Therapeutics, Inc. recently reported positive interim data from its first-in-human Phase 1 trial of ORKA-002, showing a long half-life, sustained IL-17 inhibition and a class-consistent safety profile in healthy volunteers, while outlining multiple ongoing and planned psoriasis and hidradenitis suppurativa studies across its ORKA-001 and ORKA-002 programs. A key insight for investors is the early clinical evidence suggesting ORKA-002 may enable twice-yearly maintenance dosing,...
NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

A Look At Expedia Group (EXPE) Valuation After Analyst Upgrades And Tech Progress

Recent analyst commentary around Expedia Group (EXPE) has centered on rising confidence in its tech driven model, with upgraded stock recommendations and higher published targets following progress in B2B, the One Key rollout, and share buybacks. See our latest analysis for Expedia Group. At a share price of US$271.14, Expedia Group has seen a 23.89% 90 day share price return and a 59.63% 1 year total shareholder return, suggesting recent momentum after a softer past month. If this shift in...
NasdaqGS:UBSI
NasdaqGS:UBSIBanks

Did Earnings Beat, Buyback and Piedmont Deal Just Shift United Bankshares' (UBSI) Investment Narrative?

In late 2025 and early 2026, United Bankshares completed a US$27.37 million buyback of 700,000 shares, or about 0.5% of its stock, while reporting fourth-quarter 2025 earnings and revenue that exceeded Wall Street expectations and delivered strong year-on-year sales growth. The combination of record 2025 earnings, benefits from the Piedmont Bancorp acquisition, and active share repurchases underscored solid capital strength and cash generation alongside better-than-expected quarterly...
NasdaqGS:WAY
NasdaqGS:WAYHealthcare Services

Waystar Holding (WAY) Valuation Check After New Agentic Intelligence Capabilities For AltitudeAI Platform

Waystar Holding (WAY) has put its new agentic intelligence capabilities for its AltitudeAI platform in the spotlight, targeting more automated healthcare revenue workflows, just as it prepares for presentations at key industry conferences. See our latest analysis for Waystar Holding. Despite the recent product announcement and upcoming conference appearances, Waystar Holding's share price performance has been weak. The 30-day share price return shows a decline of 9.18%, the 90-day share price...
TSX:MFI
TSX:MFIFood

A Look At Maple Leaf Foods (TSX:MFI) Valuation After Dividend Hike And 2026 Revenue Growth Guidance

Maple Leaf Foods (TSX:MFI) has given income focused investors fresh information to consider, with a 10% uplift in its quarterly dividend and new 2026 revenue guidance targeting mid single digit growth from 2025. See our latest analysis for Maple Leaf Foods. At a share price of CA$25.31, Maple Leaf Foods has had a mixed run in recent months, with a 90 day share price return of 10.94% decline but a 1 year total shareholder return of 43.55% suggesting that longer term momentum has been stronger...
TSE:9029
TSE:9029Transportation

Higashi Holdings (TSE:9029) Net Margin Improvement Tests Bearish Narratives In Q3 2026

Higashi Holdings (TSE:9029) has just posted its Q3 2026 scorecard, with revenue of ¥15.7b and basic EPS of ¥63.79, set against trailing twelve month revenue of ¥55.9b and EPS of ¥196.01 that reflects earnings growth of 53.2% over the past year. The company has seen quarterly revenue move from ¥12.7b in Q3 2025 to ¥15.7b in Q3 2026, while basic EPS shifted from ¥45.89 to ¥63.79. Trailing twelve month revenue and EPS have stepped up from ¥45.8b and ¥126.90 a year earlier to ¥55.9b and ¥196.01,...
NYSE:ORA
NYSE:ORARenewable Energy

Ormat’s Sage Geosystems Deal and Indonesia Win Might Change The Case For Investing In ORA

In January 2026, Ormat Technologies announced a US$25 million equity investment in Sage Geosystems and a long-term geothermal power purchase agreement with Switch, alongside securing Indonesia’s Telaga Ranu Geothermal Working Area concession. Together, these moves expand Ormat’s access to next-generation geothermal technology, deepen its role in data center decarbonization, and extend its project pipeline in Indonesia’s energy transition program. We’ll now examine how Ormat’s collaboration...
NGM:PLEJD
NGM:PLEJDElectrical

A Look At Plejd’s (NGM:PLEJD) Valuation After Robust Full Year Earnings Release

Earnings trigger investor focus on Plejd Interest in Plejd (NGM:PLEJD) has picked up after the company reported its full year 2025 results, with higher sales, revenue and net income, and earnings per share that exceeded the previous year. See our latest analysis for Plejd. The full year earnings release appears to have coincided with strong momentum, with a 90 day share price return of 43.35% and a year to date share price return of 76.49%. Over a longer stretch, the 3 year total shareholder...
OM:ERIC B
OM:ERIC BCommunications

Ericsson (OM:ERIC B) 12% TTM Margin Surge Tests Bearish Earnings Decline Narrative

Telefonaktiebolaget LM Ericsson (OM:ERIC B) has wrapped up FY 2025 with fourth quarter revenue of SEK 69.3b and basic EPS of SEK 2.57, capping off a trailing twelve month net income of SEK 28.4b and EPS of SEK 8.53. Over recent quarters the company has seen revenue move from SEK 72.9b in Q4 2024 to SEK 69.3b in Q4 2025, while quarterly EPS shifted from SEK 1.43 to SEK 2.57 as trailing net profit margin reached 12% versus 0.01% a year earlier. This points to materially different earnings power...
NYSE:LMND
NYSE:LMNDInsurance

Lemonade’s FSD Insurance Launch Prompts Fresh Look At Valuation And Growth Expectations

How Lemonade’s FSD Product Could Matter for Investors Lemonade (LMND) is putting its data centric model to the test with Lemonade Autonomous Car insurance, a new product for Tesla Full Self Driving that cuts per mile rates by about 50% when FSD is engaged. For you as an investor, the key questions are how this first of its kind product, backed by Tesla vehicle data and rolling out initially in Arizona and Oregon, might influence Lemonade’s growth profile, risk exposure, and long term...
NasdaqGS:PLMR
NasdaqGS:PLMRInsurance

Is It Too Late To Revisit Palomar Holdings (PLMR) After Its Strong Multi‑Year Rally?

If you are wondering whether Palomar Holdings at around US$124.95 is still a sensible entry or hold after a strong run, the key question is how that price stacks up against its underlying value. The stock has seen a 20.7% return over the last year and a very large 3 year return, even though the shorter term picture shows a 2.7% decline over 7 days, an 8.1% decline over 30 days, and a 5.2% decline year to date. Recent attention on the stock has focused on its position in the insurance sector...
TSX:GGD
TSX:GGDMetals and Mining

GoGold Resources (TSX:GGD) Is Up 18.4% After Broad Q1 Output Decline Has The Bull Case Changed?

GoGold Resources Inc. reported its first-quarter 2026 operating results for the period ended December 31, 2025, showing lower production of silver, gold, copper, zinc, and silver-equivalent ounces compared with the same quarter a year earlier. The broad-based decrease in output across all key metals highlights operational pressures that may prompt investors to reassess how the company is progressing against its production plans. With recent share price strength and silver-equivalent output...
NasdaqGS:ICHR
NasdaqGS:ICHRSemiconductor

Why Ichor Holdings (ICHR) Is Up 5.5% After Upgraded Q4 2025 And 2026 Revenue Outlook

Ichor Holdings, Ltd. recently updated investors with preliminary unaudited guidance, indicating at least US$240 million in revenue for the first quarter of 2026 and slightly above-midpoint revenue for the fourth quarter of 2025. This combination of stronger-than-previously-indicated fourth-quarter results and a higher starting point for 2026 signals improving operational momentum and order visibility. We’ll now look at how this improved revenue outlook and upgraded fourth-quarter guidance...
NYSE:KMI
NYSE:KMIOil and Gas

Kinder Morgan (KMI) Is Up 5.8% After Record Earnings, Higher Dividend and $10 Billion Backlog - Has The Bull Case Changed?

Kinder Morgan reported past fourth-quarter 2025 results with revenue of US$4,508 million and net income of US$996 million, capping a year in which sales reached US$16.94 billion and net income totaled US$3.06 billion. The company paired these record earnings with a US$10 billion project backlog concentrated in natural gas infrastructure and a 2% dividend increase to US$0.2925 per share for the quarter (US$1.17 annualized). Next, we will look at how Kinder Morgan's expanding US$10 billion...